Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.

Bulk Drug Park in the country :PIB

The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park

Funds for R&D in drug discovery and manufacturing :PIB

An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.

Sumitomo Pharma Oncology receives Orphan Drug Designation for DSP-0390 for the treatment of brain cancer

The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people

Enveric Biosciences advances drug development for mental health indications

Advancing to IND-enabling studies with multiple drug candidates

Govt introduces 'Draft of New Drugs, Medical Devices and Cosmetics Bill, 2022'

The Bill aims to amend and consolidate the law relating to the import, manufacture, distribution and sale of drugs, medical devices and cosmetics

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates

AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing

AMPEL BioSolutions' predicts drug options with RNA analytics & machine learning

Pfizer submits new drug application to the U.S. FDA for Paxlovid

Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk

Lonza to invest 500 mn in commercial drug product fill & finish facility

The investment will enable the company to provide customers with a complete and integrated end-to-end solution